CoChat

Diagnosis of Breakthrough Fungal Infections in the Clinical Mycology Laboratory: An ECMM Consensus Statement

Open access
Jenks, Jeffrey D., Gangneux, Jean-Pierre, Schwartz, Ilan S., Alastruey-Izquierdo, Ana, Lagrou, Katrien, Thompson III, George R., Lass-Flörl, Cornelia, Hoenigl, Martin, Investigators, European Confederation of Medical Mycology (ECMM) Council · 2020 · Journal of Fungi

Published version of a preprint

The DOI matches its Crossref record; 138 of the 139 references it cites were found in a registry or an index.

Abstract

Breakthrough invasive fungal infections (bIFI) cause significant morbidity and mortality. Their diagnosis can be challenging due to reduced sensitivity to conventional culture techniques, serologic tests, and PCR-based assays in patients undergoing antifungal therapy, and their diagnosis can be delayed contributing to poor patient outcomes. In this review, we provide consensus recommendations on behalf of the European Confederation for Medical Mycology (ECMM) for the diagnosis of bIFI caused by invasive yeasts, molds, and endemic mycoses, to guide diagnostic efforts in patients receiving antifungals and support the design of future clinical trials in the field of clinical mycology. The cornerstone of lab-based diagnosis of breakthrough infections for yeast and endemic mycoses remain conventional culture, to accurately identify the causative pathogen and allow for antifungal susceptibility testing. The impact of non-culture-based methods are not well-studied for the definite diagnosis of breakthrough invasive yeast infections. Non-culture-based methods have an important role for the diagnosis of breakthrough invasive mold infections, in particular invasive aspergillosis, and a combination of testing involving conventional culture, antigen-based assays, and PCR-based assays should be considered. Multiple diagnostic modalities, including histopathology, culture, antibody, and/or antigen tests and occasionally PCR-based assays may be required to diagnose breakthrough endemic mycoses. A need exists for diagnostic tests that are effective, simple, cheap, and rapid to enable the diagnosis of bIFI in patients taking antifungals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jof6040216

Cites

138 of 138 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 138 references

Research works printed but not linked: 1

  1. WHO Guidelines Approved by the Guidelines Review Committee (2018). Guidelines for the Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children: Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection, World Health Organization.

Cited by

See all 44

Metadata

Authors
Jenks, J. D., Gangneux, J.-P., Schwartz, I. S., Alastruey-Izquierdo, A., Lagrou, K., Thompson III, G. R., Lass-Flörl, C., Hoenigl, M., & Investigators, E. C. O. M. M. (. C.
Affiliations
  • University of California San Diego (US)
  • Inserm (FR)
  • University of Alberta (CA)
  • Mycology Reference Laboratory, National Centre for Microbiology. Instituto de Salud Carlos III. Majadahonda, 28222 Madrid, Spain
  • Universitair Ziekenhuis Leuven (BE)
  • Division of Infectious Diseases, Department of Internal Medicine and Department of Medical Microbiology and Immunology
  • Division of Hygiene and Medical Microbiology, Medical University of Innsbruck, 6020 Innsbruck, Austria
  • Medical University of Graz (AT)
Corresponding author
Hoenigl, Martin
Venue
Journal of Fungi
Publisher
MDPI AG
Published
2020-10-11
Volume
6
Issue
4
Pages
216
ISSN
2309-608X (ISSN-L)
OpenAlex
W3081623395
Cited by
44
References
139
Citations by year
2026: 5 · 2025: 7 · 2024: 4 · 2023: 8 · 2022: 8 · 2021: 10 · 2020: 2
FWCI
0.92
Type
journal article
Language
en
Open access
Locations
  • Journal of Fungi (publishedVersion, cc-by)
  • Preprints.org (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • SERVAL (Université de Lausanne) (publishedVersion, cc-by)
  • SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
  • Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
  • IRIS (submittedVersion, cc-by)
  • Lirias (submittedVersion, other-oa)
  • HAL (submittedVersion, other-oa)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Funders
  • Pfizer
  • Gilead Sciences
  • Medpace
  • Regeneron Pharmaceuticals
  • Wellcome Trust (101873/A/13/Z)
  • Cidara Therapeutics
  • Mylan
  • Amplyx
  • Nabriva Therapeutics
  • Deutsche Forschungsgemeinschaft (390661388, EXC2030)
  • Astellas Pharma
  • Shionogi
  • Da Volterra
  • Medical Research Council (MR/N006364/2)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
Keywords
antifungal therapy, invasive mold infections, invasive aspergillosis, endemic mycoses, fungal culture, PCR-based assays, serologic tests, antifungal susceptibility testing, diagnostic recommendations, histopathology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnosis of Breakthrough Fungal Infections in the Clinical Mycology Laboratory: An ECMM Consensus Statement. https://app.cochat.ai/papers/10.3390/jof6040216
The paper
Jenks, J. D., Gangneux, J.-P., Schwartz, I. S., Alastruey-Izquierdo, A., Lagrou, K., Thompson III, G. R., Lass-Flörl, C., Hoenigl, M., & Investigators, E. C. O. M. M. (. C. (2020). Diagnosis of Breakthrough Fungal Infections in the Clinical Mycology Laboratory: An ECMM Consensus Statement. Journal of Fungi. https://doi.org/10.3390/jof6040216

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.